Menu

Image of the Day: Medicinal Millipedes

Certain lemurs in the forests of Madagascar eat millipedes to protect themselves from parasitic infections of the gut.

Jul 31, 2018
Sukanya Charuchandra
A red-fronted lemur (Eulemur rufifrons) chews on millipedes in the Kirindy Forest of Madagascar. 
LOUISE PECKRE

Madagascar’s red-fronted lemurs (Eulemur rufifrons) eat millipedes to both prevent and cure infections caused by some parasites, according to a study published in Primates yesterday (July 30). 

“Eating millipede secretions may be a way of self-medication,” Louise Peckre, a doctoral student at the Leibniz Institute for Primate Research in Germany, says in a statement.  

Besides eating the creatures, the primates also applied munched-up millipedes to the areas surrounding their genitalia and anuses and to their tails. Peckre and colleagues  believe the millipedes produce a compound called benzoquinone, known to repel mosquitoes, which may help the lemurs keep parasites out of their gut and away from their anuses.

L.R. Peckre et al., “Potential self-medication using millipede secretions in red-fronted lemurs: combining anointment and ingestion for a joint action against gastrointestinal parasites?,” Primates, doi:10.1007/s10329-018-0674-7, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.